Genome&Company: Q1 2026 Operating Loss Widens but Fundraising Succeeds, Pipeline Progresses
Consolidated Q1 2026 revenue: KRW 5.8B (down from KRW 6.4B YoY); operating loss: KRW 6.1B (wider than Q1 2025); net loss: KRW 6.8B (slightly improved from KRW 7.1B YoY).
Successful fundraising: Issued 4th CB of KRW 27B (Mar 2026) and post-quarter equity offering of KRW 7B (Apr 2026). Cash & equivalents at quarter-end: KRW 47.1B (vs KRW 15.6B at end-2025).
Total liabilities: KRW 60.1B (vs KRW 30.4B at end-2025), including current CB of KRW 14.6B and derivative liabilities of KRW 21.9B. Increased financial leverage.
Key pipeline: GEN-001 phase 2 completed in gastric cancer (ORR 19%); GENA-104 licensed to Ellipses Pharma, phase 1 ongoing; ADC candidates in preclinical. No dividends or share buybacks.